Literature DB >> 2390669

Caffeine-induced behavioural stimulation is dose- and concentration-dependent.

G B Kaplan1, N T Tai, D J Greenblatt, R I Shader.   

Abstract

1. The relationship between plasma and brain caffeine and metabolite concentrations and behavioural stimulation was investigated over a 4 h time course. 2. CD-1 mice receiving single intraperitoneal doses of caffeine-sodium benzoate solution (caffeine doses: 0, 20, and 40 mg kg-1) were evaluated in an activity monitor, and their plasma and brain caffeine and metabolite concentrations were determined by high performance liquid chromatography (h.p.l.c.). 3. Kinetic variables for caffeine at low and high caffeine doses were: volume of distribution (Vd), 1.16 and 0.88 l kg-1; plasma elimination half-life (t1/2), 1.25 and 1.62 h; brain t1/2, 0.93 and 1.30 h; clearance, 0.64 and 0.38 l h-1 kg-1, respectively, with Vd and brain t1/2 differing significantly between the two caffeine doses. 4. Low-dose caffeine stimulated vertical behaviours significantly more than high-dose, during the first 150 min post-dosage; both doses stimulated vertical behaviours significantly more than vehicle treatment. 5. Low-dose and high-dose caffeine stimulated horizontal and stereotypic behaviours equivalently, during the first 150 min post-dosage; both doses stimulated these behaviours significantly more than vehicle. 6. Only later, 150 min post-dosage, did high-dose caffeine stimulate all behaviours significantly more than both low-dose and vehicle treatment; this occurred when caffeine concentrations had fallen to approximately 10 micrograms g-1 in the high-dose group. 7. The maximal stimulant effects of caffeine occurred in an intermediate concentration range, between 10-20 micrograms g-1, while lower and higher concentrations produced either no additional stimulation or decrements in activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2390669      PMCID: PMC1917803          DOI: 10.1111/j.1476-5381.1990.tb15824.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Purinergic inhibition of diazepam binding to rat brain (in vitro).

Authors:  P J Marangos; S M Paul; A M Parma; F K Goodwin; P Syapin; P Skolnick
Journal:  Life Sci       Date:  1979-02-26       Impact factor: 5.037

2.  Effects of caffeine and theophylline on activity of rats in relation to brain xanthine concentrations.

Authors:  A Thithapandha; H M Maling; J R Gillette
Journal:  Proc Soc Exp Biol Med       Date:  1972-02

Review 3.  Adenosine receptors in the central nervous system: relationship to the central actions of methylxanthines.

Authors:  J W Daly; R F Bruns; S H Snyder
Journal:  Life Sci       Date:  1981-05-11       Impact factor: 5.037

4.  Up-regulation of brain [3H]diazepam binding sites in chronic caffeine-treated rats.

Authors:  P H Wu; V L Coffin
Journal:  Brain Res       Date:  1984-02-27       Impact factor: 3.252

5.  Antagonistic effects of caffeine and yohimbine in animal tests of anxiety.

Authors:  H A Baldwin; A L Johnston; S E File
Journal:  Eur J Pharmacol       Date:  1989-01-10       Impact factor: 4.432

6.  Chronic caffeine consumption increases the number of brain adenosine receptors.

Authors:  J P Boulenger; J Patel; R M Post; A M Parma; P J Marangos
Journal:  Life Sci       Date:  1983-03-07       Impact factor: 5.037

7.  Caffeine consumption and anxiety: preliminary results of a survey comparing patients with anxiety disorders and normal controls.

Authors:  J P Boulenger; T W Uhde
Journal:  Psychopharmacol Bull       Date:  1982-10

8.  The effects of caffeine on plasma MHPG, subjective anxiety, autonomic symptoms and blood pressure in healthy humans.

Authors:  D S Charney; M P Galloway; G R Heninger
Journal:  Life Sci       Date:  1984-07-09       Impact factor: 5.037

9.  Interaction between methylxanthines and the benzodiazepine receptor.

Authors:  R L Weir; R E Hruska
Journal:  Arch Int Pharmacodyn Ther       Date:  1983-09

10.  Adenosine receptors and behavioral actions of methylxanthines.

Authors:  S H Snyder; J J Katims; Z Annau; R F Bruns; J W Daly
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

View more
  8 in total

1.  Is GABA involved in the development of caffeine tolerance?

Authors:  S Mukhopadhyay; M K Poddar
Journal:  Neurochem Res       Date:  1998-01       Impact factor: 3.996

2.  Rewarding and aversive doses of caffeine alter activity but not conditioned place preference induced by ethanol in DBA/2J mice.

Authors:  Alfredo Zuniga; Christopher L Cunningham
Journal:  Pharmacol Biochem Behav       Date:  2019-10-31       Impact factor: 3.533

3.  Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease.

Authors:  K Xu; Y-H Xu; J-F Chen; M A Schwarzschild
Journal:  Neuroscience       Date:  2010-02-16       Impact factor: 3.590

4.  Penetration of adenosine antagonists into mouse brain as determined by ex vivo binding.

Authors:  J Baumgold; O Nikodijevic; K A Jacobson
Journal:  Biochem Pharmacol       Date:  1992-02-18       Impact factor: 5.858

5.  Caffeine Controls Glutamatergic Synaptic Transmission and Pyramidal Neuron Excitability in Human Neocortex.

Authors:  Amber Kerkhofs; Ana C Xavier; Beatriz S da Silva; Paula M Canas; Sander Idema; Johannes C Baayen; Samira G Ferreira; Rodrigo A Cunha; Huibert D Mansvelder
Journal:  Front Pharmacol       Date:  2018-01-04       Impact factor: 5.810

6.  Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice.

Authors:  Y Kapelyukh; C J Henderson; N Scheer; A Rode; C R Wolf
Journal:  Drug Metab Dispos       Date:  2019-05-30       Impact factor: 3.922

7.  Acute doses of caffeine shift nervous system cell expression profiles toward promotion of neuronal projection growth.

Authors:  Nancy Y Yu; Andrea Bieder; Amitha Raman; Enrichetta Mileti; Shintaro Katayama; Elisabet Einarsdottir; Bertil B Fredholm; Anna Falk; Isabel Tapia-Páez; Carsten O Daub; Juha Kere
Journal:  Sci Rep       Date:  2017-09-13       Impact factor: 4.379

8.  Defining a Time Window for Neuroprotection and Glia Modulation by Caffeine After Neonatal Hypoxia-Ischaemia.

Authors:  Elena Di Martino; Erica Bocchetta; Shunichiro Tsuji; Takeo Mukai; Robert A Harris; Klas Blomgren; Ulrika Ådén
Journal:  Mol Neurobiol       Date:  2020-01-23       Impact factor: 5.590

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.